GlassScriptPhysician profile
Gregory D Anselmi
NPI 1477697761
$32,725.83
in general payments reported to CMS, 2019-2025
6 companies · $165 in 2025
The $165 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $8,233 · 2021: $12K · 2022: $411 · 2023: $386 · 2024: $18.32 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $386 · Consulting Fee: $150 · Education: $34.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $385.84 |
| Consulting Fee | $150.00 |
| Education | $34.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $32,298.40 | 2019-2025 | Tysabri, Vumerity |
| Celgene Corporation | $172.95 | 2021-2023 | Zeposia |
| Alexion Pharmaceuticals, INC. | $83.48 | 2022-2025 | Ultomiris |
| Horizon Therapeutics Plc | $75.76 | 2021-2023 | Uplizna |
| Sunovion Pharmaceuticals INC. | $61.92 | 2019 | |
| Amgen INC. | $33.32 | 2019-2024 | Uplizna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Anselmi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.